AveXis is a clinical-stage gene therapy company developing innovative treatments for rare and life-threatening genetic diseases.    Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1.
AveXis is a rapidly growing leader among gene therapy biotech companies and continues to establish relationships with academics, biotechnology and pharmaceutical companies, and healthcare investors.

Company Growth (employees)
Bannockburn, US
Size (employees)
114 (est)+10%
AveXis was founded in 2010 and is headquartered in Bannockburn, US

AveXis Office Locations

AveXis has an office in Bannockburn
Bannockburn, US (HQ)
160 2275 Half Day Rd

AveXis Data and Metrics

AveXis Financial Metrics

$, USD

Net income (FY, 2016)

(83 m)

EBIT (FY, 2016)

(83.4 m)

Market capitalization (23-Jun-2017)

2.2 b

Closing share price (23-Jun-2017)


Cash (31-Dec-2016)

240.4 m
AveXis's current market capitalization is $2.2 b.
$, USDFY, 2016

R&D expense

58.9 m

General and administrative expense

24.5 m

Operating expense total

83.4 m


(83.4 m)

Interest income

402.8 k

Net Income

(83 m)
$, USDFY, 2016


240.4 m

Current Assets

245.2 m


24.2 m

Total Assets

270.6 m

Current Liabilities

24.4 m

Preferred Stock


Additional Paid-in Capital

387.7 m

Retained Earnings

(141.6 m)

Total Equity

246.1 m

Financial Leverage

1.1 x
$, USDFY, 2016

Net Income

(83 m)

Depreciation and Amortization

64.6 k

Accounts Payable

163.9 k

Cash From Operating Activities

(48 m)

Capital Expenditures

(19.2 m)

Cash From Investing Activities

(19.2 m)

Cash From Financing Activities

245.4 m

Interest Paid

14.7 k

Free Cash Flow

(67.2 m)
Y, 2016

Financial Leverage

1.1 x

AveXis Market Value History

AveXis Online and Social Media Presence

AveXis Company Life and Culture

You may also be interested in